Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 244 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prevnar Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

NCT00239694
View directory record Official record
Conditions
Aging
Interventions
Pneumococcal Vaccine, Meningococcal Vaccine
Biological
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01349569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 4 Interventional

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382
View directory record Official record
Conditions
Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions
Prevnar, Pneumovax
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

NCT03537508
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
MenACYW conjugate vaccine, MenACYW-135 conjugate vaccine, DTaP-IPV//Hib vaccine, Pneumococcal 13-valent conjugate vaccine, Pentavalent rotavirus vaccine, Hepatitis B vaccine, Measles, mumps, rubella (MMR) vaccine, Varicella vaccine, Hepatitis A vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
65
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 19, 2026, 5:25 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma

NCT01245673
View directory record Official record
Conditions
Myeloma
Interventions
Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide), MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)
Biological · Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Cyclosporine, Hepatitis A Vaccine (Inactivated), Efavirenz, Pneumococcal Conjugate Vaccine, Heptavalent, Rabies Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
15
States / cities
Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting

NCT05452941
View directory record Official record
Conditions
Pneumonia
Interventions
Diagnostic test on urine samples
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
12,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
40
States / cities
El Centro, California • Fontana, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

NCT04526574
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
Experimental 20-valent pneumococcal conjugate vaccine (20vPnC), Saline, Influenza vaccine
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
1,796 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
63
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 19, 2026, 5:25 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

NCT06824194
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, Rotarix, RotaTeq, Vaxelis vaccine, Varivax, Priorix, VAQTA, Havrix
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
103
States / cities
Birmingham, Alabama • Guntersville, Alabama • Oneonta, Alabama + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 4 Interventional

Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency

NCT07135427
View directory record Official record
Conditions
Alpha 1-Antitrypsin, COPD, Antibody Deficiency
Interventions
20-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional

Maternal Immunization To Prevent Infant Otitis Media

NCT00617682
View directory record Official record
Conditions
Otitis Media
Interventions
PNCRM9, Placebo comparator
Biological
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Bloomington, Minnesota • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

NCT00993668
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Certolizumab pegol
Other · Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
41
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

NCT03620162
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13™, V114, RotaTeq™, Pentacel™, RECOMBIVAX HB™, HIBERIX™, M-M-R™ II, VARIVAX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

NCT06128915
View directory record Official record
Conditions
Aging
Interventions
vaccine
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 211 Days
Enrollment
3,230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
106
States / cities
Bessemer, Alabama • Birmingham, Alabama • Centreville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™

NCT00772928
View directory record Official record
Conditions
Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Interventions
Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
1,167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
23
States / cities
Montgomery, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

NCT00282308
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Drug · Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 19, 2026, 5:25 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

NCT06838000
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Months to 17 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
17
States / cities
Paramount, California • Doral, Florida • Hialeah, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 19, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Immunogenicity of PCV-7 Vaccine in VLBW Infants

NCT00273325
View directory record Official record
Conditions
Pneumococcal Infections, Streptococcus Pneumoniae, Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 3 Months
Enrollment
368 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
10
States / cities
Birmingham, Alabama • Palo Alto, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 19, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49

NCT07284654
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
31 valent pneumococcal conjugate vaccine, PCV20, PCV21
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,049 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
30
States / cities
Birmingham, Alabama • Chinle, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 5:25 AM EDT